This story is from the BioSpectrum Asia Feb 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia Feb 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Australia creates new transparent blood vessel-on-a-chip
A University of Sydney team has successfully created a transparent microchip with the potential to reduce the testing of new drugs to treat heart disease on animals before proceeding to clinical trials.
University of Sydney launches institute in Vietnam to focus on public health & sustainability
The University of Sydney Vietnam Institute has been officially launched and will build on a network of leading researchers and educators to benefit communities in Vietnam and beyond through impactful research and engagement.
Why global pharma companies choose India for GCCs
India’s pharmaceutical industry is globally recognised for its capabilities in research and manufacturing and for its skilled labour. The country’s attractiveness as a destination for Global Capability Centres GCCs) is underpinned by several key factors, including cost-efficiency, a vast talent pool, robust infrastructure, and strong regulatory support.
How technology and AI are democratising healthcare
As Artificial Intelligence AI) continues to shape the way we work and live, we must ensure that we are tapping into its full potential when it comes to the healthcare space. By leveraging its unique capabilities to address the accessibility barriers that we see in our healthcare centres in the APAC region and equip policymakers and industry leaders with the knowledge, tools and information to change and democratise our healthcare systems.
"We're seeing Al-powered diagnostic tools enhancing accuracy and efficiency, across multiple sectors"
In July 2024, Advanced MedTech Holdings (AMTH) appointed Wong Yau Chung as its new Group Chief Executive Officer, succeeding his role as Group Chief Operating Officer. With a core focus in urology devices and contract manufacturing services, the company serves millions of patients and physicians across 100 countries worldwide. Wong Yau Chung interacts with BioSpectrum Asia and shares his vision for Advanced MedTech Holdings' future and insights on key trends shaping the medtech industry.
Addressing Root Causes of Brain Disorders with Innovative Therapeutics
Neuroscience is a complex market encompassing a range of neurological conditions.
PAHO and World Bank launch PROTECT project to strengthen pandemic response in South America
The Pan American Health Organization (PAHO) and the World Bank have launched the PROTECT Project, an initiative to improve pandemic response in seven South American countries.
WHO prequalifies first self-test for hepatitis C virus
The World Health Organization (WHO) has prequalified the first hepatitis C virus (HCV) self-test which can provide a critical support in expanding access to testing and diagnosis, accelerating global efforts to eliminate hepatitis C.
Psylo partners with University of Sydney to deliver psychedelic treatments in Australia
The University of Sydney's Brain and Mind Centre has partnered with Psylo, a global biotechnology startup and pioneer in nonhallucinogenic psychedelic drugs, to develop innovative treatments for psychiatric and neurological disorders using advanced artificial intelligence technologies. Researchers at the University of Sydney's School of Psychology have developed machinelearning-guided behavioural analysis technology, which utilises high frame-rate cameras and sophisticated dataparsing techniques to predict the behavioural profiles and potential therapeutic properties of new drugs.
Hyundai Bioscience develops multi-treatment drug to treat mosquito-borne viral infections
Korea-based Hyundai Bioscience, which is preparing for a dengue fever basket clinical trial in Brazil, has successfully developed a multi-treatment drug for mosquito-borne viral infections, including dengue fever, using niclosamide as the main ingredient.